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1. Introduction 
In light of a rapidly expanding geriatric demographic worldwide, and the concomitant 
increased prevalence of glaucoma, the need for reliable and reproducible methods for 
disease progression has become increasingly necessary. Given the high costs and morbidity 
of treatment, whether medical, laser, or incisional, the ability to detect disease and to further 
demonstrate progression allows glaucoma specialists to make more informed decisions 
regarding both the initiation, and advancement of therapeutic modalities. Furthermore, our 
ability to image both the anterior segment and the optic nerve head has allowed for better 
elucidation of anatomic variants and mechanisms of secondary glaucomas, along with better 
detection of subtle glaucomatous optic neuropathies and progression of nerve fiber layer 
defects. 
The treatment of glaucoma has advanced rapidly over the past decades, yet remains a 
chronic disease requiring life long control. The expansion of the armamentarium of 
interventions possible to help retard progression of disease has allowed us to cater 
treatments to the specific needs of an individual patient. As glaucomatous damage is 
essentially irreversible, the holy grail of glaucoma treatment, regardless of etiology, is early 
detection of a progressive disease state. Intraocular pressure (IOP) remains the only 
modifiable risk factor for glaucoma patients, and continues to serve as the metric by which 
the success of therapeutic intervention is judged. The need for accuracy of these 
measurements has led to a better understanding of ocular tissue properties, and potentially 
their relative effects on disease progression. 
In terms of diagnosis and management of glaucoma, progress has been made since the days 
when visual field testing remained the only option for the detection and documentation of 
disease and its progression. As traditional perimetry provides a functional assessment of a 
patient’s disease state, the need for reliable structural measurements has resulted in the 
development of a multitude of technologies. The relationship between structural damage 
and functional loss, however, is often complicated, and much remains to be elucidated at the 
current time. Since structural and functional assessments give us different information, both 
are often used in conjunction for the detection and treatment of glaucoma. Understanding 
the limitations of both assessments is tantamount when considering various therapeutic 
algorithms. Ultimately, it remains the role of the clinician to determine an individual patient’s 
risk of progression. This is optimally achieved by determining the level of intervention 
necessary to prevent functional loss, balancing the risks, side effects, and costs of treatment. 
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2. Assessment and measurement of intraocular pressure 
As intraocular pressure (IOP) remains the only modifiable risk factor for glaucoma, the 
importance of consistent and accurate measurements cannot be overstated. Reduction of 
IOP remains the cornerstone for the treatment of glaucoma, as adequate and reproducible 
data on neuroprotective agents is currently lacking. Given that all forms of tonometry have 
limitations, the reference standard for IOP assessment continues to be Goldmann 
applanation tonometry (GAT). A brief review of the principle behind IOP measurement is 
provided here. GAT relies on the Imbert-Fick principle, and is in part based upon a 
standardized GAT applanation diameter of 3.06mm. The IOP is inferred from the force 
needed to flatten this standardized area of the central cornea. Therefore, it is intuitive that 
central corneal pathologies and properties will affect these IOP measurements.  
For patients with high corneal astigmatism, it is important to take the average of two 
measurements 90 degrees apart by adjusting the applanation tip accordingly. GAT 
measurements need to be furthermore adjusted according to standard corneal pachymetry 
nomograms, although no one nomogram that exists that is universally accepted. A range of 
IOP correction from 1.1 to 7.14mm Hg/100 microns of corneal thickness exists in the current 
literature1. It is of interest that the clinical utility of these adjustments remains somewhat 
controversial, and that other corneal biomechanical properties may be of higher utility (See 
Ocular Response Analyzer below). Regardless, it is likely that corneal pachymetry 
measurements below 500 microns underestimate IOP, and those over 600 microns 
overestimate the measurement. A variety of tonometers have been developed in response to 
these properties, and some are discussed within this section. 
2.1 Tonopen (Reichert technologies depew, NY) 
The Tonopen is a modified Mackay-Marg tonometer, and is commercially sold as the 
Tonopen XL, and more recently, the Tonopen Avia. Mackay-Marg tonometers work on the 
principle that the applanating force to flatten a cornea (transuducer with a 1.5 mm 
applanation tip) must be equivalent to the counteracting force from within the eye. The 
transducer only measures the pressures at the center of the applanator, in contrast to the 
GAT, and is theorized to be less dependent on intrinsic corneal properties. The Tonopen 
contains a micro strain gauge attached to a 1.0 mm transducer, sampling at a rate of 500 
measurements per second. This high sampling rate allows the Tonopen to provide accurate 
and reproducible IOP measurements. The Tonopen has several major advantages over GAT. 
It does not require a slit lamp, and is therefore not dependent on patient positioning, 
allowing for easy use outside the examnination room setting.. It further provides objective 
results, and requires less skill and training than GAT to perform. The Tonopen is 
particularly useful in children and non-cooperative patients. The surface area of applanation 
is one-third that of the GAT, and the ability to measure IOP from a non-central location may 
be an advantage in patients with certain corneal pathologies.  
A study done in the earlier years of the Tonopen on 15 eyes which needed corneal glue, or 
had band keratopathy, demonstrated that the Tonopen was equivalent to the GAT when the 
unaffected area was applanated The study further concluded that the Tonopen grossly 
overestimated the IOP when the affected area was tested2. A large cross-sectional study of 
over 2000 primary care patients who were screened for ocular hypertension (OHTN) with 
the Tonopen described no adverse effects of tonometry, and further determined the 
incidence of OHTN and primary open angle glaucoma (POAG) to be 4.89% and 1.04% 
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respectively. Broman, et al.3, examined 230 glaucomatous eyes with the Tonopen, GAT, 
Ocular Response Analyzer (ORA- see below), and further obtained measurements of central 
corneal thickness (CCT), axial length, corneal curvature, corneal astigmatism, central visual 
acuity, and refractive error. The IOP measured was noted to be lowest by the Tonopen, and 
highest by the ORA. Interestingly, it was found that the GAT was least affected by corneal 
pachymetry, and corneal hysteresis (see ORA below) was correlated with CCT. The authors 
concluded that corneal parameters affect tonometers in different ways. Lester, et al.4 in an 
analysis of 104 patients found that the Tonopen XL gave similar results to GAT in only 62% 
of patients, and in subgroup analysis, found that the Tonopen XL underestimates IOP when 
GAT was above 20mm Hg.  
2.2 Ocular Response Analyzer (ORA: Reichert instruments, depew, NY) 
The Ocular Response Analyzer is a modified non-contact tonometer, which measures 
previously un-recordable corneal biomechanical properties. These properties are thought to 
be the result of viscous damping of corneal tissue. The ORA utilizes a rapid air impulse, 
combined with a highly sensitive optical system, to record applanation pressures when the 
cornea is both maximally deformed inwards, and then once again on reformation. The 
average of the two IOP measurements is termed IOPg, to denote the fact that it is the 
equivalent of the correlated GAT. The difference between the two IOP measurements is 
termed corneal hysteresis (CH) (Figure 1-2). The ability to measure hysteresis allows for 
further derivations of other newer metrics, such as corneal-corrected IOP (IOPcc) and the 
corneal resistance factor (CRF). These derived metrics eliminate the need for corneal 
pachymetry compensation of IOP. The IOPcc is derived from a normative database of 
patients undergoing keratorefractive surgery, and “compensates” the IOP based on corneal 
properties, not corneal thickness. CRF is a measurement of the cumulative effects of both the 
viscous and elastic resistance encountered by the air jet while deforming the corneal surface, 
and is derived from CH measurements using various algorithms. ORA measurements have 
proven to be particularly useful in patients with corneal edema and some secondary 
glaucomas, where IOPg can serve as a surrogate for GAT when it is not possible. Patients 
with abnormal ORA hysteresis measurements may be at higher risk for corneal ectasia and 
possibly post keratorefractive surgery complications as well5. 
A study of 90 eyes (30 normal, 30 with POAG, 30 pseudoexfoliative) was recently performed 
with the ORA, and corneal hysteresis was found to be significantly lower in 
pseudoexfoliatives when compared to the controls and POAG patients6. Another recent 
review of 108 POAG patients demonstrated both lower corneal hysteresis and resistance 
factor measurements when compared to those of ocular hypertensives and controls7. In a 
prospective cross-sectional study of 117 POAG patients with asymmetric visual fields, 
Anand et al8 demonstrated that abnormal ORA parameters were significantly associated 
with the eye with the greater visual field defect. Neither corneal pachymetry, nor GAT, were 
significantly different between the eyes. These findings suggest that the ORA is able to 
detect subtle differences in asymmetric glaucoma, when GAT and CCT measurements are 
symmetric. 
Lastly, Ang et al performed a prospective comparative analysis of 40 patients with normal 
tension glaucoma (NTG) with 41 diagnosed with POAG, demonstrating higher hysteresis 
measurements in the NTG group. The highest recorded GAT measurement was also 
statistically significantly correlated with lower hysteresis and higher resistance factor 
values. These findings suggest that alterations in corneal biomechanical properties may 
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occur in response to chronically elevated IOP9. It is clear that the ORA is able to distinguish 
corneal biomechanical properties that were previously undetectable. As our understanding 
of the clinical relevance of these parameters improves, the predictive and diagnostic utility 
of ORA will likely lead to a greater adoption of this technology. 
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Fig. 1. Ocular Response Analyzer (ORA). The ORA results from both eyes are displayed in 
graphical form, and are referred to as the “Signal Time Response” curves. The dynamic air 
puff to the cornea leads to two applanation events (inward and outwards), and the delays in 
these events are due to intrinsic corneal biomechanical properties. The Y-axis is the 
“Pressure/Signal Amplitude”, and the X-axis is time in msec. The solid curve which peaks 
in the center of the plot is the pressure (air pulse). The bimodal peaked line represents the 
applanation signal. The first peak represents the “in-signal”, when the cornea is flattened 
inwards by the air-puff. The second peak represents the “out-signal”, when the cornea 
essentially “unflattens” back to its original state. The intersection of the pressure and signal 
plots at both peaks represents the two applanation measurements respectively. The average 
of the two pressures is the calculated IOPg, or Goldmann-correlated IOP. The difference 
between the two pressures is termed corneal hysteresis (CH), and is thought to be due to the 
viscous damping effects of the corneal tissue. The normal range of CH varies significantly 
from 8-16mm Hg, with the value of 11mm Hg considered normal. The IOPcc and CRF are 
derived from the CH. The IOPcc is the estimated IOP given the CH of a cornea, and is 
considered to be independent of pachymetry, etc. The CRF provides an estimate of the 
overall resistance of the cornea, and normal values range similar to the CH 
2.3 Pascal dynamic contour tonomoter (DCT) 
The Pascal DCT (Zeimer Ophthalmics, Port, Switzerland) was developed in response to the 
large degree of variability of IOP measurements obtained by GAT, with respect to various 
corneal properties and biomechanics. It further eliminates the subjective nature of GAT by 
providing a slit-lamp mounted digital readout of the IOP. The advantages of the digital 
readout, along with the resultant reductions in intra-observer variability, are intuitive in a  
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busy clinical setting. Measurement of the ocular pulse amplitude (OPA) , a metric estimating 
the quality of ocular blood flow, is further displayed digitally. The SensorTip™ of the DCT 
is a concave applanator which houses a piezo resistant pressure sensor able to take 
approximately 100 measurements per second. A spring loaded Cantilever maintains a 
constant applanation force of 1 gram, reducing the likelihood of iatrogenic corneal injury as 
well. A major theoretical advantage of DCT, when compared to GAT, is that IOP 
measurements from DCT are not affected by corneal pachymetry. This difference is 
especially useful for keratorefractive and keratoconic10patients, where thin corneas and 
astigmatism greatly affect GAT measurements. The DCT clearly addresses many of the 
major shortcomings of standard GAT. DCT likely will play a larger role in glaucoma  
 
 
Fig. 2. ORA of glaucoma patient 
The ORA scans of a patient show extremely an extremely high IOPg in both eyes, with the 
right eye being significantly higher than the Left (28.9 mm Hg, 20.4 mm Hg). CH values are 
low in both eyes, with an IOPcc even higher than IOPg (31.0 mm Hg OD, 22.7 mm Hg OS). 
The intraocular pressures of this patient by GAT have ranged from 12m Hg-18mm Hg on 
medical therapy, significantly lower than the measurements by the ORA. It is likely that the 
ORA is demonstrating a gross underestimation of this patient’s IOP control. If functional 
and structural analysis continues to show progression, it is likely that this patient will need 
more aggressive IOP management than that being demonstrated by serial GAT. As with all 
testing, it is important to reproduce abnormal results prior to advancing to any therapeutic 
intervention 
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management, especially given that data generated from the DCT can be wirelessly integrated 
into many electronic medical record (EMR) systems. A hand-held DCT has been developed 
recently, and results have been shown to be consistent with the slit-lamp mounted model11.  
The DCT has been widely studied, and the current body of literature supports its use 
clinically. A retrospective review of 200 patients by Ang, et al.9 demonstrated poor 
correlation of DCT with GAT measurements that had been corrected with six different 
pachymetry compensation formulae. Gunvant, et al12 examined 120 eyes, and demonstrated 
that the Ehlers formula for GAT correction actually reduced agreement with DCT 
measurements. This study demonstrates that simple GAT corneal correction factors may be 
inadequate to compensate for complex corneal biomechanics. Kotecha, et al13, examined 100 
patients with GAT, ORA, and DCT, and concluded that the DCT demonstrated the best 
repeatability and reproducibility. Interestingly, ORA and DCT generally measured the IOP 
to be 2 mm higher than GAT in this study. Sullivan-Mee, et al14 performed a similar analysis 
on 126 eyes, and found that all three forms of tonometry (GAT, ORA, and DCT) had similar 
repeatability and reproducibility, concluding from their data that the ORA and DCT are 
acceptable alternatives to GAT in routine clinical practice.  
2.4 Icare® rebound tonometry (IRT) 
Rebound tonometry, commercially available as the Icare tonometer TA01i (Tiolat Oy, 
Helsinki, Finland), has shown tremendous promise in the realm of pediatric ophthalmology 
and community screenings in particular. The Icare tonometer does not require topical 
anesthesia, and is able to provide rapid digital IOP measurements painlessly. The handheld 
device is first stabilized on the patient’s forehead, and a small disposable rebounding probe 
briefly applanates the cornea. It is able to measure the IOP in microseconds, obviating the 
need for anesthesia and prolonged measurements, making the technology especially useful 
for children and special needs patients. The probe is briefly magnetized by an induction coil 
prior to firing, and the tonometer calculates and digitally displays the IOP from the 
generated induction current. It is important to note that IRT is likely subject to the same 
constraints as GAT with respect to various corneal parameters.  
Flemmons et al15collected GAT and IRT measurements from 71 pediatric glaucoma patients, 
and found that the IRT measurements were within 3mm Hg of GAT in 63% of patients. It 
was further noted that the IOP was higher by IRT than GAT in 75% of patients measured. 
Scuderi, et al,16 in a clinical study of 93 patients, examined the validity and limitations of 
IRT. They concluded that IRT was comparable to other nonconventional tonometers, and 
can replace GAT when it is not available. Munkwitz, et al17 similarly examined 75 patients 
with GAT and IRT, and found that the IRT performed well within 3mm Hg for 
normotensive patients. However, in patients with IOPs ranging from 22-60 mm Hg, the IRT 
was shown to have larger variability than the GAT. This result potentially reduces the 
validity of IRT measurements in ocular hypertensive patients. 
One of the most challenging aspects of glaucoma management is an absence of IOP data 
between office visits. Compliance rates likely change in the days preceding office visits, and 
extrapolating IOP over time from limited data points has serious limitations. In diabetic and 
hypertensive patients, inter-visit monitoring of blood pressure and blood glucose offers 
internists a great deal of information regarding the efficacy of treatment for these diseases. 
The possibility of home monitoring of IOP by IRT was addressed in a recent study by 
Asrani, et al. They observed excellent inter- and intra-observer variability (less than 3mm 
Hg) in 100 patients that performed IRT on themselves, compared with IRT and GAT 
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performed by a technician18. The possibility of home monitoring of IOP may have particular 
significance for patients where large diurnal IOP variability is suspected given normal 
measurements at office visits. 
3. Standard automated perimetry (SAP) and short wavelength automated 
perimetry (SWAP) – Functional assessment of the glaucoma patient 
SAP, or static perimetry, is most commonly performed by the Humphrey or Octopus 
perimeter. Alternately, manual (kinetic) perimetry, is most commonly performed with the 
Goldmann perimeter, although it is important to note that some automated perimeters do 
have kinetic testing functionality. SAP serves as a nonspecific assessment of visual function, 
and is designed to detect loss of sensitivity to light perception. This is traditionally done 
with a white stimulus on a standardized white background of uniform luminescence. 
However, newer testing paradigms which isolate specific wavelengths of light (see SWAP 
testing below) have been introduced for certain clinical indications. SAP serves as a global 
metric of functional loss. In clinical practice, this means that visual field deficits may 
represent a disease process anywhere from the ocular surface to the visual cortex. 
Characteristic patterns of deficit allow the practitioner to anatomically localize the site of 
injury, and are tremendously useful in the diagnosis and monitoring of many disease states. 
It is important to note that any visual field defect that is suspected to obey the vertical 
midline warrants further neurological assessment. The temporality and congruity of the 
field deficits further provide useful clues to the etiology of the defects. Bitemporal lesions 
generally localize pathology to the sella turcica adjacent to the optic chiasm, whereas 
homonomous defects are generally post-chiasmal. Highly congruous homonomous defects, 
especially with macular sparing, often localize to occipital pathology.  
SAP testing relies on a variety of strategies, which ultimately determine the threshold 
necessary to reliably detect the presence of a stimulus in predetermined locations within the 
visual field. Algorithms and testing strategies have been constantly advancing to maximize 
sensitivity and specificity, while reducing test time and patient fatigue. Given the wide 
variety of options, it is imperative that the clinician not only chooses the correct test, but also 
furthermore accounts for an individual patient’s ability to reliably perform that test. 
The decision to advance treatment based on visual field analysis is inherently fraught with 
confounding factors. While the advent of structural analysis (see below) have allowed for 
some quantification of glaucomatous defect, the necessity for analysis and documentation of 
functional disease progression with perimetry remains a vital component of glaucoma 
management. This is especially the case when there are disparities between clinical 
examination, perimetry, and structural analysis. An improved understanding of the 
limitations of standard perimetry and structural analysis allows the astute clinician to avoid 
treatment errors. This is particularly important given the high levels of morbidity associated 
with many of the interventions presently available. The following sections aim to highlight 
the strengths and weaknesses of the wide range of testing modalities currently available. 
3.1 Humphrey field analyzer (HFA)  
One of the most commonly utilized perimetry devices is the HFA, with over 35,000 units in 
use currently worldwide. Indeed, many of the landmark glaucoma trials such as the Ocular 
Hypertensive Trial (OHTS)19, Advanced Glaucoma Intervention Study (AGIS)20, and 
Collaborative Initial Glaucoma Treatment Study (CIGTS)21to name a few, used this form of 
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perimetry to diagnose and detect functional glaucomatous progression. HFA analysis is the 
current gold standard for clinical trials, allowing for older studies to be appropriately 
compared. Recent advancements in progression analysis software by multiple vendors have 
increased the clinical utility of serial SAP testing by allowing for greater detection of subtle 
changes.  
The choice of the most appropriate HVF should be based upon a wide variety of 
considerations. Some of these considerations include the extent of the visual field that needs 
to be tested, the intensity and size of the stimulus needed, and the best suited testing 
strategy for the clinical question being analyzed (i.e. screening vs. monitoring progression, 
etc.). An important caveat is that once a reliable visual field is obtained, it is advisable to 
utilize the same testing strategy as much as possible to reliably detect disease progression 
over time.  
3.1.1 Degrees of visual field tested 
The major options on standard HVF perimetry are 10-2, 24-2, 30-2, and the less commonly 
performed 60-2. The first number refers to the number of degrees around the fovea that will 
be tested (i.e. a 10-2 test 10 degrees of the visual field centered at the fovea). The second digit 
which is currently always “2”, refers to the protocol type which tests points on either side of 
the horizontal and vertical meridians, as opposed to points on the meridians themselves. 
Testing points directly on the meridia is denoted with a “1” as the second digit. The “1” 
strategy is particularly useful in neuro-ophthalmic evaluation, to highlight the presence of 
vertical midline defects, for example. In general, the use of 10-2 testing is reserved for 
patients with very advanced glaucoma to detect subtle progression in an extremely 
constricted field, and for patients with suspected maculopathy. The 60-2 strategy can be 
applied in patients where peripheral defects detected by smaller field analyses require 
further confirmation, however patient fatigue and artifacts may limit the clinical utility of 
this strategy. 
The choice between 24-2 and 30-2 is somewhat variable between practitioners, and there are 
advantages and disadvantages to each test. Many glaucoma specialists follow patients with 
24-2 testing in lieu of full 30-2 testing as it has been demonstrated that both tests have 
approximately equal sensitivity and specificity19 in the detection of glaucomatous field 
damage. The 30-2 paradigm can lead to significantly more fatigue for patients given the 
additional test spots in the periphery of the visual field. The 30-2 tests one more row of 
points in the peripheral visual field compared to the 24-2. This area of the field is most 
sensitive to rim, lid, and other artifacts, thereby reducing its clinical utility in some cases. As 
the detection of subtle field changes necessitates accurate testing (see below: reliability 
indices), the choice of a 24-2 paradigm may allow for improved reliability and more 
clinically meaningful data. Some clinicians choose to order a 30-2 test as the baseline, and 
assuming that it is normal, will follow patients with 24-2 testing. It is important to note that 
often multiple tests need to be performed to set a reliable baseline, as field testing accuracy 
generally improves along a variable learning curve. In patients having difficulty with 
increased test time, it is appropriate to set a baseline with the most extensive test that a 
patient can reasonably tolerate (see below: testing strategies) Important testing specifications 
are reviewed below: 
• 10-2: The points adjacent to the horizontal and vertical meridians test 1 degree of the 
visual field; points tested peripheral to these points are 2 degrees apart 
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• 24-2 and 30-2: The points adjacent to the horizontal and vertical meridians test 3 degrees 
of the visual field; points tested peripheral to these points are 6 degrees apart 
In a patient with a subtle maculopathy, affecting only a few degrees of the central visual 
field, defects can easily be missed by the 24-2 and 30-2 based on the aforementioned testing 
specifications, as the scotoma could fall in the region between the tested points. Alternately, 
dense paracentral/arcuate scotomas characteristic of glaucomatous optic neuropathies can 
“blacken” out an entire 10-2 field, and the 24-2 or 30-2 paradigms are far better suited.  
a. Screening considerations 
Screening protocols are variable amongst practitioners and practices. Large volume 
screenings for glaucoma are often performed with Humphrey Matrix Analyzers/ (FDT) 
based on the test time needed to perform the analysis. It is appropriate for “high risk” 
patients being screened (eg Strong family history of glaucoma, ocular hypertensives, 
IOP/cup-to-disc asymmetry, etc.) to perform more extensive perimetry with SITA-fast 
protocols (see below). Patients with positive screening tests warrant further work-up, often 
with structural and corneal biomechanical analyses. 
b. Other considerations 
As HFA analyses are based on age-matched controls, it is imperative that the correct birth 
date is entered prior to testing. The age groups of patients in the database are stratified into 
10 year increments. For example, a 59 year old patient will be compared to age matched 
controls between the ages of 50-60. It is common, therefore, for patients to have deterioration 
of their visual field as they progress through each decade of life. Alternately, 
“improvements” in the visual field can be seen immediately after the patient’s age increases 
to the next decade stratification. Furthermore, assessment of the mental and physical status 
of an elderly patient to determine whether they will be able to tolerate the high levels of 
concentration required to perform the test.  
Refractive errors, especially presbyopic errors, need to be neutralized with the appropriate 
loose lenses, and vertex distances/head positioning optimized. Astigmatic correction over 
1.25D should be neutralized along with spherical aberration. The HVF will determine the 
optimal neutralization from manifest refractions accounting for a target distance of 30cm. 
Reassessing head position relative to refractive neutralization is critical during testing, as 
rim artifacts can be generated by the lenses if head positioning is not adequately monitored. 
Furthermore, prismatic deviation caused by high power lenses need to be accounted for 
when testing is analyzed, and peripheral rim defects discounted appropriately in these 
cases. Pupil size is able to be measured by HFA, and is displayed with the results. Pupil size 
generally less than 2-3mm can lead to artifactual loss of threshold sensitivity of both central 
and peripheral fields22. This is of particular importance in following patients on miotic 
therapy for glaucoma. Pharmacological dilation of the pupil in these cases may help limit 
the effects of the miotic pupil. Patients should be consistently dilated for subsequent fields if 
this strategy is employed. Changes in the refractive error secondary to pharmacological 
dilation are likely negligible in the largely non-presbyopic patient demographic that 
commonly undergo perimetric evaluation.  
A standard background light intensity of 31.5 asb (apostilbs) is used for the HVF, to match 
the scotopic light conditions outlined by Goldmann perimetry standards. HVF targets come 
in sizes ranging from 0.25 mm2 to 64.00 mm2 represented by Roman numerals I through V 
(see Goldmann Visual Fields below). Typically, a size III stimulus (4 mm2) is used in patients 
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with good visual acuity (usually at least 20/200 or better). In these cases of decreased visual 
acuity, the use of larger size V (64 mm2) test stimulus may be helpful, although many 
clinicians will opt for Goldmann Visual Fields for these low vision patients. Stimulus 
intensity, color, and duration can furthermore be varied by the operator based upon clinical 
needs.  
Gaze tracking is possible with all HVF machines, and the reliability of an individual test can 
be further analyzed beyond the reliability indices calculated for each field. A real time 
fixation monitor is displayed at the bottom of each visual field printout. Upward deflections 
represent the moment a patient saccades away from a target, and downward deflections 
represent a tracking failure commonly secondary to blinking. 
3.1.2 Testing algorithms – Swedish interactive testing algorithm (SITA) 
SITA testing was designed to optimize visual field accuracy while reducing testing time. It is 
based on the concept of “threshold”, which is a term that is defined as the intensity of light 
that a patient can detect 50% of the time. The threshold represents the minimal amount of 
light intensity that can be reliably detected. SITA testing determines this threshold by 
presenting points with varying intensities using a “bracketing” technique. Specifically, this 
technique involves measuring intensities above and below the threshold, as defined above. 
This technique is much more efficient than full threshold protocols, and generally is able to 
maintain a high degree of concordance in a much shorter time period. The SITA algorithm is 
dynamic, and the stimuli are timed based on an individual patient’s response time. 
Algorithms are age-matched, so proper patient data entry is imperative. SITA-Fast and SITA 
standard algorithms remain options that can reduce test time by about 70% and 50%23, 
respectively, when compared with full threshold tests. The differences between the 
protocols lies in the variability in response allowed when determining threshold values, 
with the SITA standard being more rigorous in repetition of points. In other words, the 
SITA-FAST strategy has a lower level of confidence needed to be achieved at each point 
relative to SITA-Standard. The SITA-fast protocol utilizes the expected thresholds based on 
normative population databases. The utilization of these normative assumptions increases 
the efficiency of the test, but is limited by the fact that it does not account for threshold 
variability at the individual level. The SITA fast protocol is generally more than adequate for 
screening examinations and for those patients who cannot perform SITA standard 
secondary to fatigue. Most glaucoma specialists rely on SITA standard testing to monitor for 
subtle changes indicating progression. This is particularly critical in the regions of the visual 
field surrounding an existing scotoma. A study by Budenz, et al demonstrated an overall 
sensitivity of 98% and 95% for SITA standard and SITA fast protocols when compared to 
full threshold testing. The same study demonstrated sensitivity in patients with mild 
glaucomatous damage as 92% and 85% respectively24. Specificity was determined to be 96% 
for both algorithms. 
3.1.3 Short wavelength automated perimetry (SWAP) – Blue-on-yellow perimetry 
SWAP testing is based upon the concept that glaucoma is characterized by damage to cells 
in the visual pathway that are more sensitive to blue light, with a peak activity at 440 
nanometers. Blue cones in the photoreceptor layer of the retina eventually synapse in the 
koniocellular layers of the lateral geniculate body, via small bistratified retinal ganglion 
cells. The fact that SWAP testing isolates one type of ganglion cell should not imply that 
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these cells are necessarily the first to be affected by glaucomatous injury. Moreover, SWAP 
testing avoids the masking effects of inherent redundancies within the visual pathways by 
isolating one particular system.25,26 
SWAP testing is generally more fatiguing than SAP, and is also much more affected by lens 
opacification and drusen in patients with macular degeneration. Recent development of 
SITA-SWAP testing has helped reduce test duration while maintaining sensitivity. The 
stimulus size for the blue target in SWAP testing is larger than that of SAP (equivalent to 
Goldmann V vs. III sized targets, respectively). More light is needed to activate the blue 
cone system27, and although the blue target is generally less bright, the larger test stimulus 
size partially compensates for it. The caveat is, that a larger test stimulus can over estimate 
fixation losses in patients with relatively small blind spots, even though fixation maybe 
maintained.  
Many studies have demonstrated the ability of SWAP testing to detect visual field 
abnormalities earlier than SAP testing28,29. A recent publication demonstrated less 
persuasive results regarding the early predictive abilities of SWAP testing. However, 
methodological differences between Johnson’s original data from the prior decade may help 
explain the varied results30. Other reports indicate that patients with visual field defects on 
SAP demonstrate dramatically larger defects when tested with SWAP31-33. As data is 
continually being collected regarding SWAP testing in glaucoma patients, a better 
understanding of the protocol’s benefits and limitations will help elucidate the role of SWAP 
testing in functional assessment of the glaucoma patient. At the time of this publication, 
SWAP testing largely remains the test most commonly used in younger patients with high 
clinical suspicion for glaucoma. This is especially the case in patients with previous normal 
SAP testing.  
3.1.4 Reliability indices 
In order to make determinations about clinically significant functional progression, it is 
imperative that visual fields are as reliable and reproducible as possible. Assessment of a 
glaucomatous scotoma by reliable perimetry is expected to fluctuate given the natural history 
of the disease and the manner in which we quantify defects. Alternately stated, seemingly 
progressive visual field loss can often “reverse” with serial testing, indicating that the 
etiology of the deterioration may indeed be non-physiological. The establishment of a blind 
spot corresponding to the position of the optic nerve is accomplished by placing testing 
points within this region during reliable fixation. It is even more challenging to separate 
fluctuation from progression when analyzing visual fields that are considered “unreliable”. 
The establishment of an adequate baseline is important clinically, and essential if 
progression analysis is desired (see GPA below). 
Fixation losses are measured by introducing stimuli into the physiological blind spot, and 
monitoring whether patients are able to detect them. A fixation loss indicates that the blind 
spot has moved (i.e. the patient has refixated to an alternate location within the perimeter). 
False positives are defined as patient responses when no stimulus is present. False negative 
responses are defined as a lack of detection of a suprathreshold stimulus (i.e. not being able 
to detect a more intense stimulus after the threshold is determined).  
Reliable fields generally are recommended to have false positive and negative rates fewer 
than 35%, and fixation losses less than 20%. In clinical practice, many patients are not able to 
adequately perform the testing regardless of algorithm, and alternate means of documenting 
functional progression are necessary. Birt, et al.,33 demonstrated in a review of 768 visual  
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field test from 106 glaucoma patients, that only 59.5% of test were considered reliable by the 
aforementioned criterion. Elevating the fixation loss threshold criterion from 20% to 33% 
increased the number of fields meeting reliability standards to over 75%. Newkirk34, et al 
further demonstrated that artificially introducing false positives of 33% to a visual field 
improved the calculated mean deviation (MD) by 6dB; an amount that can easily mask 
progressive damage. Vingrys et al35demonstrated similar results, suggesting that the cutoffs 
for reliability of false positive results be reduced to 20% or less. Bengtsson, et al.36, hve 
shown that false positive rates are the least variable in test-retest paradigms, and are likely 
to be the most reliable index of visual field accuracy based on the SITA algorithms.  
3.1.5 Glaucoma Hemifield test/analysis (GHT) 
The GHT was developed by Asman, et al in the early 1990s to measure asymmetries in 
threshold sensitivity around the horizontal meridian. It functionally analyzes five 
corresponding pairs of mirror image sectors in the superior and inferior horizontal fields, 
corresponding to the normal anatomy of the retinal nerve fiber layer. Outer edge, temporal, 
and blind spot points are excluded from the analysis, and can be used with either the 30- or 
24-2 protocols. Abnormal GHT values indicate asymmetry around the horizontal meridian, 
and allows for rapid evaluation of zone defects that affect the superior or inferior hemifields 
in particular37 The results are further stratified into 5 categories: “Outside Normal Limits”, 
“Borderline”, “Generalized Reduction of Sensitivity”, “Abnormally High Sensitivity”, and 
“Within Normal Limits”. The definition of “Outside Normal Limits” is based upon defects 
between the respective upper and lower paired sectors greater than what would be expected 
in 1% of the normative database, or a sum difference at 0.5% normal population level. 
“Borderline” results indicate the same criterion at the 3% normal population level. Katz, et 
al analyzed the rate of incident field loss after one abnormal GHT, and found that GHT is 
not a consistent criterion for defining incident field loss. They further concluded that the use 
of two or three consecutive abnormal fields to define incident field loss makes it more likely 
that subsequent test results will be abnormal38. Susanna, et al. further analyzed the ability of 
the GHT to detect early glaucomatous changes, and found the sensitivity, specificity, and 
reproducibility of the GHT to be 100,100, and 83.3% respectively39. Johnson, et al more 
recently concluded that the GHT, GHT hemifield cluster, and Pattern Deviation plots 
provided the highest sensitivity and specificity of all the visual field metrics40 
3.1.6 Glaucoma progression analysis (GPA) 
Given the often large amounts of data provided by serial perimetry, the absolute need for 
automated detection of progressive visual field loss has lead to advancements in software 
that efficiently summarize function over time. This capability allows clinicians to rapidly 
detect areas of the visual field that have deteriorated from baseline threshold values. These 
are defined by the user as the first reliable field or fields (full threshold or SITA). The data 
output of GPA analysis summarizes the probability of the presence of glaucomatous 
progression. It factors in normal fluctuation from a large database, and subtracts out deficits 
secondary to media opacification as well. The data is summarized in probability plots, 
demonstrating the likelihood of functional progression with variably darkened triangular 
symbols. Triangles that are darker represent a portion of the visual field that has 
consistently worsened over multiple tests. A minimum of five examinations over at least 
three years must be included in GPA 2 for the linear regression results to be presented. The 
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open triangles represent deterioration from baseline with a 0.5 confidence interval, the half-
shaded triangles represent deterioration at the same point on 2 visual fields, and finally the 
darkened triangle represents deterioration at the same location on 3 visual fields. Deterioration 
is defined as greater than that of the normal fluctuation that occurs within a normative 
database. Again, the lack of a uniform definition of deterioration is a severe limitation when 
comparing progression analyses. Consensus regarding this definition continues to be the 
source of much debate. Furthermore, the clinical relevance of any defined progression must 
be evaluated on an individual case basis to avoid errors in treatment strategy. Regardless of 
the definition of progression, it is widely accepted that the accuracy of progression rates is 
vastly improved with additional data points. This functionally translates into establishing a 
reliable baseline, repeating visual fields often, and using a longitudinal analysis to 
determine the rate of progression. In this manner, the likelihood of clinically relevant 
deterioration can be most accurately assessed. 
As the assessment of glaucoma progression involves some degree of subjectivity, there are 
often discrepancies in patients who demonstrate mild changes in function. A recent review 
of 510 Humphrey visual fields of 83 eyes by 3 examiners demonstrated that clinician 
agreement of progression on sequential fields was actually better without the GPA analysis41. 
Clinician agreement (inter-observer reliability) obviously may not be an appropriate 
reference standard for the determination of disease progression given the subjective nature 
of the analysis. Another review of 90 eyes with greater than 5 reliable visual fields 
demonstrated that the GPA performed better in the detection of progression, when 
compared to a pattern deviation based visual field index (VFI)42. Another retrospective 
review of 93 glaucoma patients with 5 reliable fields concluded that there is a strong 
correlation between GPA identification of glaucomatous progression and a thorough 
objective clinical assessment of the visual fields. They further concluded that GPA could be 
a useful test to aid clinicians in the detection of glaucomatous progression, with high 
specificity, strong positive likelihood ratio, good sensitivity and negative likelihood ratio43. 
Diaz-Aleman, et al44 examined 56 eyes of 42 patients with at least 7 reliable fields, and 
compared threshold noiseless trend (TNT) to GPA, and showed that TNT had a higher 
specificity and concordance with clinical examiners than GPA.  
It is important to note that no universal definition of glaucoma, whether via a statistical 
package or point-by-point analysis, has been universally accepted. The optimal 
characterization of glaucomatous progression is the source of much of the research on 
perimetry that is currently being performed. Furthermore, as the perimetric definitions of 
progression vary significantly amongst many of the major landmark glaucoma studies, 
comparisons of results between the major trials has been limited. Clinically relevant models 
derived from these studies lack reproducibility, and no one index has been shown to be 
superior at the time of this publication (Figures 3-8).  
While a useful adjunctive tool, GPA has had variable success when compared to other 
methodologies. It is our opinion that GPA serves as a useful tool in conjunction with other 
standard examination techniques when compared to grossly comparing serial HVF 
examinations without point by point analysis. The software will unlikely replace careful 
clinical examination utilizing a gestalt technique in its current clinical application. 
Monitoring the rate of visual field deterioration by multiple metrics, while accurately 
predicting the onset of functional loss with particular regard to projected life expectancy, is 
likely the optimal strategy in determining optimal treatment.  
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Fig. 3. HVF single field analysis with progression analysis summary: OD 
This HVF is an example of the normal scan of the right eye of a patient being followed as a 
glaucoma suspect. Important demographic information is included at the top of the 
printout, including the date of birth. The type of visual field, in this case, Central 24-2 
Threshold Test, is listed directly below. The type of Fixation Monitor (Gaze/Blind Spot), 
Stimulus Size (III) and Color (White stimulus on White Background), and the pupil diameter 
in mm (3.0 mm) is displayed in the next line, along with the date of the examination. The 
standard background intensity of 31.5 asb is used for this test, and the BCVA is further 
inputted from the chart. Reliability indices including Fixation Losses, False Positive and 
False Negative Errors, are displayed as a ratio and percentage respectively. The testing 
strategy is also displayed (SITA-Standard). Making clinical assessments of progression 
based upon serial analysis of fields utilizing different strategies should be avoided. The 
optimal refractive correction for the 30cm test distance is displayed, and it is one of the 
essential roles of the perimetrist to accurately correct the patient with large diameter loose 
lenses. The test duration is also recorded, and can give insight into a patient’s performance. 
Longer test durations are likely to be prone to errors secondary to fatigue, and may have 
poorer reliability indices as well. Often the second eye tested will have lower test times, 
indicating the possibility of a learning curve effect during that perimetry session. Alternating 
the first eye tested for subsequent fields may “reverse” this phenomenon when unexplained 
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asymmetry is found. The threshold sensitivities, along with mean and pattern deviations are 
plotted along with probability analysis for a given defect. Darker shaded boxes within the 
field indicate a higher probability that the defect is valid compared to age-matched controls 
(range from 0.5% - 5%). The glaucoma hemifield test (GHT) is displayed in the upper right 
hand corner of this scan, indicating in this case that no asymmetry was found between the 
upper and lower sectors analyzed. Finally, the GPA summary plot is found in the boxed 
results section. In this case, no progression was detected. Symbols are placed at any test 
point location that has changed from baseline by more than the variability you would see in 
19 out of 20 stable glaucoma patients at the approximately the same stage of the disease. The 
dates of the baseline and previous fields, used by the software to determine the likelihood of 
progression, are further displayed. The accuracy of the progression analysis improves 
dramatically with both a reliable baseline, and a larger number of follow-up fields. 
 
 
Fig. 4. Single field analysis: OS 
In contrast to the right eye of the same patient, the left eye is demonstrating early changes in 
the pattern deviation of the inferior field (indicated by variably shaded boxes). The GHT is 
considered “Outside Normal Limits”, and the GPA has determined the presence of “Possible 
Progression”. The half-shaded triangles indicate p-values < 5% on 2 consecutive fields. 
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Fig. 5. GPA Summary OD 
The GPA summary displays the grey scale for the baseline test, along with some of the 
indices for each of the tests displayed, including MD, PSD, GHT, Reliability Indices, Pupil 
size, and BCVA. The rate of change is also plotted over time (patient’s age in years) against a 
visual field index (VFI). A VFI score of 100% represents a normal visual field, and 0% 
represents completely blackened perimetry. The VFI is calculated from pattern deviation 
plots, and was developed in response to the effects of media opacity on previous metrics. 
The rate of progression as a percentage is further displayed and analyzed. In this case, a +0.1 
± 0.2%/year was determined to be a normal slope. The shaded box at the far right of the 
plots is the extrapolated final VFI given a life expectancy of approximately 100 years old and 
the calculated rate of progression. The bottom half of the printout displays the results of the 
most recent exam, and provides probability plots for point-by-point likelihood of 
progression compared to baseline and prior follow-up examinations. 
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Fig. 6. GPA summary OS 
In this case, it is demonstrated that the VFI extrapolation requires at least 5 consecutive tests 
to be considered reliable (only 4 visual fields are inputted), and a rate to be accurately 
calculated. The accuracy of this progression software significantly improves over time as 
additional fields are added to the analysis. The baseline visual fields in this patient are 
normal, in contrast to the defects noted in the most previous field detailed at the bottom of 
the printout. This patient is considered clinically to be at moderate risk of functional 
progression in this eye. 
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Fig. 7. Change analysis OD 
The Change Analysis box plots display a variety of visual field metrics in the form of 
frequency distributions. The Y-axis is valued in Db, and represents the difference between 
the observed values relative to a normative database. The actual values observed are 
displayed in a chronological fashion centered on the 0 dB point (ie no deviation from 
normal). Positive deflections (above 0 db) indicate a “better than normal” threshold, and 
negative deflections indicate “worse than normal” threshold values. In this manner, the 
highest point (top of the “T”) for each field represents the point with the highest threshold 
relative to normal. The shaded boxes for each data set indicate the percentile rank within 
each field. The highest value of the uppermost box for each data set is the 85th percentile, the 
middle represents the 50th percentile (ie half of the thresholds are above, and the other half 
below), and the bottom value represents the 15th percentile. The slope of the line for each 
visual field index is graphically displayed and then analyzed. In this example, the MD slope 
is calculated as +0.06 ± 0.26dB/year, indicating that no progression is noted during the 
testing interval. It is important to note that other diagnoses besides glaucoma can adversely 
affect the indices as well. Clinical correlation is always imperative. 
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Fig. 8. Change analysis OS 
In contrast to the right eye, the median values for the fields included are below the 0db line. 
The highest threshold points for each field (top of the “T”) are above normal limits, however 
the range of percentile rankings tend to be below the 0 dB mark. The PSD plot further 
demonstrates possible worsening of the visual field, particularly in the latest examination. 
3.2 Alternate functional assessment 
When a patient is determined by multiple attempts and strategies to be a poor test taker by 
conventional SAP, alternate strategies may need to be employed to measure the visual field 
and establish an adequate baseline. As therapeutic algorithms are often advanced (ie topical 
therapy, laser, incisional surgery) based upon demonstration of functional progression of 
www.intechopen.com
 Glaucoma - Basic and Clinical Concepts 
 
356 
disease, it is optimal for the clinician to exhaust any and all options available to determine 
the functional status of a patient. The Octopus perimeter is an alternative to the HVF, and 
offers many advantages in these patients. The Goldmann kinetic perimeter is an also 
relatively commonly used option in these patients for multiple reasons. As fixation can be 
manually monitored, patients are able to take breaks during testing, and receive coaching 
and encouragement on a point by point basis. Frequency Doubling Technology (FDT), 
Matrix analyzers, while much faster than traditional SAP, may not necessarily be 
appropriate as an alternate testing protocol for many patients. Simple confrontational visual 
fields provide only a gross estimate of visual function, and are clearly not an appropriate 
way to follow patients with, or at risk for glaucoma. 
3.2.1 Octopus visual field analyzer  
The Octopus visual field analyzer (Haag-Streit International, Koeniz, Switzerland) has had 
major advancements over the past decade, which largely developed in response to many of 
the limitations of the HVF. One of the key advancements in the technology is an improved 
fixation/blink monitor which continually tracks and accounts for fixation losses and eye 
blinking, along with automatic adjustments based on head and eye positioning relative to 
the perimeter. This additional functionality can dramatically improve the accuracy of the 
test, and further limit lens/rim artifacts that may occur with traditional SAP. Furthermore, 
the Tendency Oriented Perimeter (TOP) strategy employed by the Octopus reduces test 
duration for threshold analysis to an average of 2.5 minutes per eye, significantly reducing 
patient fatigue. The Octopus’ EyeSuite™ Progression software offers intuitive plots 
demonstrating both global and cluster progression, and has the ability to integrate structural 
assessment as well. The Octopus test stimuli and background intensities are matched to 
those of Humphrey and Goldmann perimeters (See HFA above and GVF below). 
Studies comparing the Octopus and Humphrey visual field analyzers have demonstrated 
variable results. King, et al45 demonstrated that the SITA Fast and TOP strategies were 
highly correlated in a study of 76 glaucoma patients. They did note that although the TOP 
strategy was faster than the SITA protocol, it tended to underestimate the focal visual field 
defects. A recent analysis by Lan, et al46 demonstrated a similar finding when comparing the 
Octopus to FDT (see below). Often times, the establishment of newer baselines with an 
alternate protocol proves to be a major barrier to adaptation. As with many technologies, 
ease of integration into electronic medical records has proven to be a driving force for 
changes in clinical practice. The utility of testing patients with multiple functional 
assessments remains to be determined given the likelihood of discordance.  
3.2.2 Goldmann visual field (GVF) 
The major difference between SAP and Goldmann visual field testing is that the SAP is a 
static visual field, whereas Goldmann visual field testing is kinetic, defined as perimetry 
utilizing a moving stimulus (3-5 degrees/second)47. It is important to note that the GVF may 
be used as a manual static perimeter as well, and is generally reserved for improved 
isolation of an existing scotoma. In the case of kinetic Goldmann perimetry, the moving 
stimulus is controlled by a skilled operator. This subjectivity is a major drawback, as subtle 
changes in the visual field can easily be missed given the summative variability of both the 
patient and operator48. However, given that each patient response can be carefully 
monitored, the added reliability of GVF testing makes the test clinically useful in patients 
who are unable to perform SAP. This is especially true in patients with poor central visual 
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acuity who are unable to reliably fixate for automated perimetry. This is indeed one of the 
most common reasons that GVF testing is ordered for glaucoma patients.  
An additional advantage of the GVF is that it is it the only form of perimetry that is able to 
test the entire visual field. This encompasses 60 degrees superiorly and nasally, 75 degrees 
inferiorly, and 110 degrees temporally, although there are few clinical indications that 
demand testing far peripheral points. Neuro-ophthamic evaluation for functional visual loss 
and other central processes remains another common indication for GVF testing. 
Definitions of stimuli and target sizes are summarized below. 
Stimulus size  Stimulus Intensity 
0 = 1/16 mm2  1 – 4 : represent 5dB increments 
I = 1/4 mm2  a - e : represent 1 dB increments 
II = 1 mm2 
III = 4mm2 
IV= 16mm2 
V= 64 mm2 
3.2.3 Frequency doubling technology (FDT) and the Matrix™ perimeter 
FDT perimetry is based on a phenomenon that when an achromatic sinusoidal grating ,with 
low spatial frequency, flickers at a high temporal frequency, the apparent spatial frequency 
of the grating appears to be doubled49. Glaucoma is thought to preferentially effect cells in 
the magnocellular pathway, which have been demonstrated to be more sensitive to motion 
and flicker detection50. On the other hand, theories contend that the FDT illusion is based on 
higher cortical processing, and no retinal substrate exists to account for the phenomenon51. 
Regardless, the appeal of a technology that is theoretically able to preferentially detect 
damage to this visual pathway is obvious, and the clinical utility of FDT has advanced 
remarkably over the past decades. Current screening and full threshold strategies can be 
performed in minutes, reducing the inaccuracies of testing patients that are easily fatigued 
by the duration of SAP and similar strategies (Figures 9-10). Reproducibility of FDT results 
has further been demonstrated in multiple studies52,53. The reported sensitivity of FDT 
ranged from 0.51 to 1.00, and specificity from 0.58 to 1.00 determined by a meta-analysis of 
pooled data in 2006, with similar findings in more recent data.54,55 
Nakagawa, et al.56 recently examined 39 open angle glaucoma patients with low to moderate 
IOP, comparing FDT to SAP. With almost 5 years of follow-up, they determined that FDT 
was useful for monitoring defects detected in the SAP-normal hemifield in OAG eyes with 
low-to-normal IOP. A detailed study of 60 eyes with normal SAP (“pre-perimetric 
glaucoma”) found that FDT testing was able to detect abnormalities in an astounding 65% of 
patients, of which 51% later developed defects by SAP over 4-27 months57, a clear 
demonstration of the clinical utility of FDT in early detection of disease processes. Ferraras, 
et al58 examined 278 subjects with pre-perimetric glaucoma by SAP, but with structural 
abnormalities by HRT, GDx-VCC, and OCT (see below). This study demonstrated that 20% 
of patients with structural loss had abnormalities on SWAP and FDT testing when SAP was 
found to be normal.  
The Humphrey Matrix perimeter (Carl Zeiss Meditec, Dublin, Calif) was introduced in 2005, 
as a newer generation FDT perimetry option with the implementation of multiple efficiency 
measurements to reduce test taking duration. Fixation monitoring technology has been 
implemented, as have a wide variety of testing options ranging from screening to full 
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threshold algorithms. The option of smaller stimuli able to resolve subtle maculopathies, etc. 
is a further advancement from older generation FDT perimeters.  
 
 
Fig. 9. Frequency doubling technology (FDT): Right eye of same patient on same day as HVF 
The FDT plots of the right eye of the same patient show similar metrics to the HVF single 
field analysis (See Figure 1). The total deviation plot demonstrates more damage than the 
pattern deviation plot, likely indicating the presence of a media opacity in this patient. The 
pattern deviation plot demonstrates one point , in the superior field close to the vertical 
meridian, with a p<0.5 value not detected by the HVF. The significance of this point of 
visual field loss, as with any finding, needs to be correlated clinically with structural 
examination and careful ophthalmoscopy. This may indicate a false positive value, or 
possibly an early defect that the FDT was able to resolve prior to HVF change. 
A recent prospective study of 115 glaucomatous eyes examined with the Humprey Matrix 
perimeterand SITA-SWAP demonstrated sensitivity of 87% for early glaucoma (pattern 
standard deviation was 94% and mean deviation was 91%); and nearly 100% sensitivity and 
specificity for moderate to advanced glaucoma when compared to SAP59. Another study 
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comparing FDT to SAP in 50 patients with confirmed glaucoma by SAP demonstrated 
excellent sensitivities of greater than 90%, and demonstrated that FDT had greater 
specificity than SAP in detecting more severe defects.60 These recent results certainly 
demonstrate that FDT is a technology that likely will play an increasing role in the 
functional assessment of glaucoma patients. 
 
Fig. 10. Frequency doubling technology: Left eye of same patient on same day as HVF 
The FDT plot clearly demonstrates a focal defect in the inferonasal field that corresponds to 
the HVF defects (See Figures 4-6). It is interesting to note that the MD is significantly lower 
(-11.16 dB) than that calculated from a HVF the same day (-2.11 dB). This large discrepancy 
may be indicative of the FDT’s ability to detect disease at an earlier state. However, the rate 
of change demonstrated in subsequent FDT evaluations will provide more insight into the 
likelihood of clinical relevant progression. 
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4. Structural assessment of the glaucoma patient 
The assessment of structural abnormalities of the anterior segment and the optic nerve can 
be performed utilizing a variety of technologies. Each of these diagnostic modalities offers a 
range of imaging resolutions, and the latest iterations offer extremely detailed images. 
Arguably, the largest advantage of adjunctive structural assessment is the fact that the 
measurements are purely objective (ie not subject to the inherent variability seen in all forms 
of subjective functional assessment). Another important ramification of these advancements 
is the ability to detect structural abnormalities prior to functional loss. In patients with 
documented functional loss, structural assessment further allows for quantification of the 
magnitude of defects. The detailed summary images rendered allow clinicians to actively 
engage patients in their diagnosis and treatment with simple color coded plots of the 
relevant anatomy. A great deal of research has been done utilizing these technologies, and it 
has clearly changed the manner in which clinicians diagnose, treat, and monitor disease 
progression. Furthermore, objective measurements are inherently less likely to be subject to 
test taking environments, and are therefore more translatable between practitioners. As 
structural assessments are not without limitations, it is the role of the clinician to reconcile 
discordant data, and make the most appropriate recommendations based on the totality of 
information available.  
Prior to the modern imaging techniques further described below, clinicians relied on careful 
fundoscopic examination and red-free photography to visualize the retinal nerve fiber layer. 
A recent study by Suh, et al analyzed progressing normal tension glaucoma patients with 
red-free photography, visual fields, and stereo disc photography61. Four characteristic 
progression patterns were noted including: widening of the existing defect towards the 
macula, deepening of the defect without expansion, appearance of a new defect, and finally 
widening of a defect away from the macula. It was noted that almost 95% of these patients 
exhibited widening of the defect towards the macula, and deepening of the existing defect. 
Interestingly, no progression was clinically observed on the disc stereo photographs (n=65) 
or in the visual fields (n=55) in 64 eyes (98.5%) and 46 eyes (83.6%), respectively61. Although 
useful, reproducible high quality red-free images are often difficult and expensive to obtain. 
Serial red-free photography has largely been supplanted by the newer diagnostic modalities 
presented below for more routine cases. 
4.1 Ocular coherence tomography (OCT)  
OCT is one of the technologies that has absolutely revolutionized the field of 
ophthalmology. Clinicians are now able to resolve, at the micrometer level, exceptional 
three dimensional images of ocular tissues in vivo. These detailed images have allowed us 
to follow a variety of disease states with incredible accuracy, and help monitor the 
efficacy of therapeutic interventions. OCT is based upon the principle of interferometry, 
and provides a non-invasive “optical biopsy” of almost every aspect of the ocular 
anatomy. OCT is powered by low-coherence near infrared light (820nm), and renders 
images of microstructures based upon reflected signals. The light source at this 
wavelength offers excellent tissue penetration and has an exceptional safety profile. The 
super luminescent diode light source is split, simultaneously illuminating the ocular 
tissue specified,along with an internal reference mirror. The interference patterns of the 
backscattered light is detected by photo detectors, and then graphically interpreted into a 
standardized output format.  
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4.1.1 Time-domain OCT  
This technology is used by the Stratus® OCT (Carl Zeiss Meditec, Dublin, CA), allowing for 
approximately 10 micrometer resolution at an acquisition rate of approximately 400 
scans/second. This technology has recently been somewhat supplanted by higher generation 
OCT scanners in many practices. (see Spectral Domain OCT below). The most commonly 
used protocol for glaucoma management is the Fast Retinal Nerve Fiber (RNFL) scan, with 
thinning of the RNFL serving as a surrogate for the measurement of ganglion cell loss. The 
optic nerve head can be further analyzed to determine rim volume, depth, and cup to disc 
ratio, amongst other parameters. The Fast RNFL protocol measures the thickness of the 
RNFL in a circumferential fashion around the optic nerve at around a 3.4mm diameter. The 
thicknesses of the RNFL from both eyes are then compared to an age-matched normative 
database. The results are displayed in graphical form with a color coding system designed 
to represent the severity of the thinning. The average RNFL thickness is calculated from the 
thicknesses of individually displayed measurements from all four quadrants of the optic 
nerve. Time-domain OCT has limitations with regards to resolution and data acquisition 
speeds. This is based on the fact that the technology is limited by the velocity of movement 
of-a mirror-interferometer Kanamori, et al.62 compared the RNFL scans and mean deviation 
(MD) from SAP of 237 glaucomatous eyes versus 160 controls, and found a significant 
correlation between RNFL thinning and greater MD. Furthermore, the average RNFL 
thickness proved to be the most reliable parameter in monitoring glaucomatous progression. 
Gupta, et al.63 in a recent review in the neuro-ophthalmic literature, demonstrated that 
patients with non-glaucomatous optic neuropathies had a thinner RNFL thickness than 
patients with glaucomatous optic neuropathy. Leung, et al.64 conducted a large study of 137 
eyes obtaining 1373 Fast RNFL scans, 1373 normal RFNL scans, and 1236 visual fields over a 
median period of 4 years, and determined that the Fast RNFL protocol was the most reliable 
Stratus OCT protocol to detect and follow progression in glaucomatous eyes.  
Given the objective nature of OCT scans, there is a tendency amongst clinicians to rely on 
these examinations more than functional assessment with perimetry. While this may be 
deemed appropriate in patients unable to perform perimetric evaluation reliably, the 
limitations of OCT must be taken into account as well. Reliable OCTs are often impossible in 
patients with severe surface disease, miotic pupils, dense media opacification, high axial 
length with associated peripapillary atrophy, and vitreous disease. Correlations should 
routinely be performed between OCT results and the clinical appearance of the optic nerve, 
as the scans may underestimate cupping when there is glaucomatous undermining under 
the rim tissue. 
Our group65 recently published a study further demonstrating the confounding effects of 
vitreous traction on the retinal nerve fiber layer. Approximately 110 eyes of patients were 
examined with Stratus OCT. Those noted to have partial vitreous detachments at the optic 
nerve head were found to have artifactually elevated RNFL measurements when matched to 
controls. Given the relatively high incidence of partial posterior vitreous detachments in the 
glaucoma group, it was hypothesized that RNFL damage from glaucoma may be masked by 
the effects of the vitreo-retinal interface. It was concluded from these results that both 
structural and functional assessments are imperative to determine the presence of 
glaucomatous damage in these patients in particular. Further investigation of the natural 
history of PVD, along with changes in the measured retinal nerve fiber layer by OCT, is 
currently underway. A corollary analysis of the effects of aging on vitreous separation is 
furthermore being investigated The vitreoretinal interface has been extensively examined by 
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OCT, particularly in diabetics. Ophir et al, amongst others, have performed multiple 
analyses utilizing 3-D SD-OCT (see below) to demonstrate that the subtleties of the 
vitreoretinal interface can be resolved accurately66,67.  
4.1.2 Spectral domain (SD) OCT 
SD-OCT, also known as Fourier Domain OCT or High Definition OCT (HD-OCT), is the 
latest commercially available iteration of the OCT technology at the time of this publication. 
The commercially available Cirrus® OCT (Carl Zeiss Meditec, Inc.) has tremendous 
advantages over the Stratus OCT in the evaluation and management of many eye 
conditions. SD-OCT measures the cross-spectral density, a Fourier transformation aimed to 
estimate the spectral density from a sequence of time samples. The measurements are 
performed at the detection arm of the interferometer68. This allows for much higher 
resolution and lower test times, as there are no “moving-part” limitations within the 
interferometer. Furthermore, the ability of the SD-OCT to capture approximately 20,000 
axial scans per second, compared to 400 scans/sec for the Stratus OCT, allows for 
significantly more accurate imaging. This further translates into scans that are less subject to 
micro-saccadic eye movements during data acquisition. The resultant axial resolution of the 
scans can be less than 6 micrometers. The Cirrus OCT is furthermore able to match 
anatomical landmarks from prior scans, minimizing the errors associated with scan 
misalignment. Misalignment errors are indeed an important source of confounding data 
with previous versions of the OCT. This is especially the case when longitudinal progression 
analysis is performed. Lastly the ability to render 3-Dimensional imaging of complex ocular 
anatomy is yet another major advancement.  
Many ophthalmic practices have updated the Stratus OCT to one of the SD-OCT modules in 
the recent past. It is important to note that the aforementioned differences do not easily 
allow clinicians to compare RNFL measurements between the two technologies, and 
accurate correction factors are currently lacking. The re-establishment of a new baseline 
RNFL thickness with the SD-OCT is quite commonly done in many of these cases. Knight, et 
al.69 compared the Stratus OCT to the Cirrus OCT RNFL measurements of 130 eyes with 
glaucoma relative to normal controls. They demonstrated that the RNFL thickness measured 
by the Stratus OCT tended to be higher than that of the Cirrus OCT. Sung, et al70, performed 
a similar comparative study of 60 normals, 48 glaucoma suspects, and 55 glaucoma patients, 
They demonstrated that the Cirrus OCT had better sensitivity and specificity for disease 
than the Stratus OCT, and classified a significantly higher proportion of patients as 
abnormal. Specifically, Cirrus OCT demonstrated higher sensitivity and specificity (63.6% 
and 100%) than the Stratus OCT (40.0% and 96.7%) Leung, et al.64, in a study of 128 
glaucomatous eyes over 2 years, similarly concluded that the Cirrus OCT detected 
glaucomatous changes earlier and more often that the Stratus OCT. A portion of this 
difference can be attributed to decreased measurement variability with the Cirrus OCT.  
Newer versions being developed will likely offer even greater sensitivity and specificity, 
improved resolution, and clinical progression analysis. Incorporation and evaluation of 
perimetry in the analysis will likely help bridge the current gap that exists between 
structural damage and functional loss These advancements will likely be in part possible 
with the exponentially growing adoption of electronic medical record (EMR) systems. At the 
time of this publication, significant barriers exist with respect to the interface between EMR, 
and the variety of functional and structural assessment tools that were traditionally 
designed as stand-alone technologies.  
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4.2 Confocal scanning laser ophthalmoscopy (SLO)  
Retinal imaging with a confocal scanning laser ophthalmoscope (cSLO) involves scanning a 
small laser beam over the retina, and constructing an image from the descanned reflected 
light. By applying the confocal principle, tomographic images can be produced71. The 
confocal principle involves measurement of reflected laser light which is concentrated 
through a pinhole. SLO is based upon acquiring point-by-point images from a series of 
depths, and then reconstructing them into three-dimensional topographic images.. The 
Heidelberg Retinal Tomography (HRT) unit scans the fundus with a 670-nm diode laser, 
creating a three-dimensional map of the fundus and optic nerve. This is accomplished by 
obtaining multiple optical sections at different depths using a confocal aperture72 The 
commercially available (HRT) unit has undergone advancements since the advent of the 
technology, to its current form as the HRT-III. HRT is used clinically in a similar manner to 
OCT scans in the evaluation and management of glaucoma. Exceptional imaging quality 
and newer iterations of progression analysis have made the HRT one of the leading 
structural analysis tools in practice today. HRT scans further employ eye tracking 
technology to improve the validity and reproducibility of serial examination. The analysis of 
the optic nerve head further includes a variety of metrics designed to document 
morphological variants (Figure 11). The clinical and predictive utility of these parameters 
continues to be the subject of a great deal of research and subsequent debate. As with any 
testing modality, data from the HRT needs to be correlated to an individual patient’s clinical 
picture to determine its validity.  
Kalabhoukhava, et al.72, analyzed 59 subjects with ocular hypertension and glaucoma over 
50 months with HRT, perimetry, and stereo disk photography. After expert review of the 
patients at the 50 month time point, subjects were grouped as either progressive or non-
progressive. HRT parameters (cup shape measurement, classification index, the third 
moment in contour, cup/disc ratio, cup area, rim area, and area below reference) showed 
statistically significant morphological changes in only the progressive group (ie no change 
from baseline in the “stable” group). These results effectively demonstrate the high 
diagnostic utility of HRT testing as an adjunctive assessment tool for glaucoma evaluation. 
Kilintizis, et al73, demonstrated that changes in HRT parameters of “length of contour” (LC) 
and “standard deviation of contour” (SDC) were of particular significance when comparing 
almost 100 glaucoma patients to controls. Balasubramanian, et al.74 compared HRT I and II 
parameters in 380 eyes, and concluded that the stereometric parameters were not 
significantly altered by the newer generation scans. Another study by this same group 
performed an observational cohort study of 246 eyes followed with HRT, topographic 
change analysis (TCA), SAP, and stereo photography. It was concluded from the variability 
in results that there is a great deal of discordance in the detection of longitudinal change75 
between these modalities. Somewhat conflicting assessments of the utility of the HRT, as 
with all of the aforementioned diagnostic modalities, reminds us that the clinical utility of 
any data collected greatly relies on the clinician’s subjective correlations.  
4.3 Scanning laser polarimetry (SLP) 
The original GDx (Laser Diagnostic Technologies, San Diego, CA), and newer versions with 
variable corneal compensation GDx-VCC (Carl Zeiss Meditec, Dublin, CA), analyze RNFL 
thickness with a different method than the OCT and HRT. The RNFL is birifringent 
secondary to the highly ordered microtubule arrays of the axon microtubules. As the near 
infrared laser light (780 nm) is split by the birifringent tissue, a phase shift phenomenon 
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Fig. 11. Heidelberg retinal tomography (HRT) summary of RNFL of same patient on same 
day as HVF and FDT 
Structural analysis may demonstrate an anatomical correlate to demonstrable visual field 
loss. The digital images are rendered at the top of the summary slide. The green circle 
demonstrates the limits of the area that is being examined. Centration is optimal in this case, 
and the newest generation HRT scanners are able to register and match previous scans to 
improve the reliability of progression analysis. The difference, or calculated asymmetry, 
between the two eyes is displayed in the top center of the summary printout. The difference 
in measure RNFL (OD – OS) is graphically displayed by location in the circumpapillary 
region with S= Superior, N= Nasal, I=Inferior, T=temporal, along with combinations in 
between the regions (ie TS = Temporal Superior, etc.). Negative values indicate that the left 
eye has a thicker RNFL, and positive values indicate the opposite. The circumpapillary RNFL. 
www.intechopen.com
 Management of Glaucoma in the Era of Modern Imaging and Diagnostics 
 
365 
occurs given the difference in velocity of the reflected light. RNFL thickness can be 
calculated based on the magnitude of this phase shift. As the anterior segment structures 
also demonstrate the property of biriferigence, it is necessary to subtract these effects, and 
newer versions with customized corneal compensation have proven to be much more accurate 
than prior versions utilizing a fixed compensation algorithm76. While the newest generation 
SLP is far more accurate than earlier versions, the technology is subject to some degree of 
variability in eyes that show so called “atypical birefringence patterns”. Normal patterns of 
birefringence are generally characterized by the presence of high peripapillary retardation 
superiorly and inferiorly. This pattern corresponds histologically to the distribution of the 
superior and inferior arcuate nerve fiber bundles.77 Abnormal patterns, that are considered 
normal variants, could therefore confound the data analysis and subsequent detection of 
disease. 
Kim, et al.78 measured the RNFL of 60 normal patients to 60 glaucoma patients with GDx 
VCCand Stratus OCT. The results demonstrated no significant differences between the 
instruments, with high correlations in the superior and inferior quadrants in particular. 
Pablo, et al79analyzed 181 eyes diagnosed with OHTN with GDx-VCC and Stratus OCT, and 
also found similar diagnostic accuracy between the two. Aptel, et al.80, compared 120 eyes 
with Cirrus OCT and GDx-VCC (40 normals, 40 glaucoma suspects, 40 glaucoma) compared 
with visual field sensitivity, and found that the Cirrus OCT had a stronger correlation to 
function than the GDx-VCC. Lopez-Pena81 performed a prospective study of 423 eyes 87 
normal eyes, 192 ocular hypertensive eyes, 70 pre-perimetric glaucomas and 74 glaucomatous 
eyes) to compare SAP with GDx-VCC. The results of this large study showed only weak to 
moderate correlations with RNFL measurements and visual field defects in the glaucoma 
group. The relationship between HRT structural defects with functional visual field changes 
is clearly yet to be well defined.  
5. Conclusions 
The management of glaucoma in the modern era, despite the advent of a host of 
technologies, remains more of an art than a science in many respects. Improvements in 
tonometry will continue to improve the accuracy of IOP measurement, especially as the 
effects of corneal biomechanical properties continue to be elucidated. The potential for 
accurate home monitoring will allow for better assessment of diurnal and inter-visit IOP 
control. Similarly, improved imaging techniques will allow for earlier detection of disease 
with continually improving resolution and reproducibility. It is important to consider that 
early detection of glaucoma inherently carries the risk of over-diagnosis and subsequent 
overtreatment. Rates of progression, with all of the modalities described, need to be 
established prior to the initiation or advancement of therapy. Understanding the limitations 
of the testing is imperative when making assessments regarding both structure and 
function. A gestalt approach to glaucoma management allows the specialist to amalgamate a 
host of information, and effectively cater therapies based on the information available. The 
modern age of glaucoma care has had notable advancements, and the future of glaucoma 
management will allow for the optimal care of this globally disabling disease.  
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